Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 24Recruiting 12Active not recruiting 9Terminated 7Unknown 5Withdrawn 3Not yet recruiting 3Suspended 1No longer available 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 3Gastrointestinal 1CNS 1

Conditions

Carcinoma, Renal Cell 3Glioblastoma 2Neoplasms 1Gliosarcoma 1Glioma 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 6Sunitinib 5Bevacizumab 4Sorafenib 3Radiotherapy 3Radiosurgery 3Nivolumab 3Magnetic Resonance Spectroscopy 3Interleukin-2 3Cyclophosphamide 3Axitinib 3tivozanib 2fludarabine phosphate 2durvalumab 2avelumab 2atezolizumab 2Peripheral Blood Stem Cell Transplantation 2Optical Imaging 2Nephrectomy 2Gene Expression Profiling 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2tremelimumab 1temsirolimus 1siltuximab 1sargramostim 1pazopanib 1pamiparib 1milademetan 1lenvatinib 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Renal Cell × Axitinib × Clear all
NCT04555603 2023-11-21

Axitinib Therapy Management Study

Pfizer

Withdrawn
Genitourinary

Carcinoma, Renal Cell

NCT05263609 2022-08-02

Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib

University of Oklahoma

Phase 2 Withdrawn
Genitourinary

Carcinoma, Renal Cell

NCT01441388 2011-12-20

A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.

Pfizer

Phase 1 Withdrawn
CNSGastrointestinalGenitourinary

Carcinoma, Renal Cell, Glioblastoma, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡